Recombinant human erythropoietin - 3SBio/Biolotus

Drug Profile

Recombinant human erythropoietin - 3SBio/Biolotus

Alternative Names: EPIAO; rhEPO

Latest Information Update: 09 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 3SBio; Biolotus
  • Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced anaemia

Most Recent Events

  • 08 Jul 2015 Launched for Chemotherapy-induced anaemia in Brazil (IV) (SC) (Biolotus website, June 2015)
  • 11 Jul 2011 Registered for Chemotherapy-induced anaemia in China (SC)
  • 07 Feb 2011 High dose recombinant erythropoietin is still in preregistration for Chemotherapy-induced anaemia in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top